Sun Pharmaceutical's buyout of troubled Ranbaxy Laboratories this year came with the chore of facing the issues that led the FDA to ban four Ranbaxy plants in India. But now Sun finds itself cleaning up a mess from Ranbaxy's U.S. manufacturing operation, Ohm Laboratories, which has led it to recall more than 1 million boxes of a product it produced for private-label customers.
